tiprankstipranks
Soleno Therapeutics Corrects Q4 Financial Reporting Error
Company Announcements

Soleno Therapeutics Corrects Q4 Financial Reporting Error

Don't Miss our Black Friday Offers:

Soleno Therapeutics Inc (SLNO) has issued an update.

A revised press release by Soleno Therapeutics, Inc. has corrected a minor reporting error in their financial results for Q4 and the full year of 2023. The adjusted figure for general and administrative expenses is now accurately stated as $4,140 for the quarter ending December 31, 2023, rectifying the previous misstatement of $4,410. This update ensures investors have precise information for their financial assessments.

See more insights into SLNO stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlySoleno Therapeutics announces U.S.. FDA to ended review period for NDA
TipRanks Auto-Generated NewsdeskSoleno Therapeutics Reports Q3 Progress and Financials
TheFlySoleno Therapeutics reports Q3 EPS($1.83) , consensus (63c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App